237 DNA and RNA alterations associated with colorectal peritoneal metastases: A systematic review Table 1. Continued Reference Year Country Study Design Patient Inclusion Period Reasons for Patient Exclusion No. of Subjects No. of Genes Investigated Aim of the Study Start End Heublein et al. 24 2018 Germany CH 1988 2012 - 23 754 miRNAs miRNA profiling of primary CRC tissue to identify miRNAs potentially associated with defining the site of metastatic spread in CRC. Jacob et al. 25 2021 Germany CC 01/2005 12/2014 Lack of any of the baseline variables or specimens, HNPCC or FAP co-malignancies. 18 770 To identify genes associated with the metastatic route in CRC. Jacob et al. 26 2021 Germany CH - - Missing FFPE tissue of the primary tumor, co-malignancies, Lynch-syndrome or other hereditary diseases. 18 770 To elucidate the link between immunosurveillance and organotropism of metastases in CRC by evaluating different gene signatures and pathways. Kawazoe et al. 27 2015 Japan CH 01/2013 06/2014 - 264 4 To evaluate mutations in Japanese mCRC patients and assessing their corresponding effects on the efficacy of anti-EGFR therapy. Lan et al. 28 2015 Taiwan CH 03/2000 01/2010 No tissue sample available in the biobank. 1492 7 To analyze mutation spectra of the PI3K and RAS pathways in CRC and the associations with sites of metastases of recurrence. Lan et al. 29 2021 Taiwan CH - - Patients who had stage I–III CRC, received emergent surgery, or who did not have available tumor or preoperative serum samples in the biobank. 95 10 To evaluate the concordance of mutation patterns between tumor tissue DNA and circulating cell-free DNA in stage IV CRC patients and to analyze relationship between the mutational patterns and site of metastases. 11
RkJQdWJsaXNoZXIy MTk4NDMw